2023
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC ☆
Mok T, Lopes G, Cho B, Kowalski D, Kasahara K, Wu Y, de Castro G, Turna H, Cristescu R, Aurora-Garg D, Loboda A, Lunceford J, Kobie J, Ayers M, Pietanza M, Piperdi B, Herbst R. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC ☆. Annals Of Oncology 2023, 34: 377-388. PMID: 36709038, DOI: 10.1016/j.annonc.2023.01.011.Peer-Reviewed Original ResearchConceptsTissue tumor mutational burdenImproved overall survivalProgression-free survivalTumor mutational burdenOverall survivalKEYNOTE-042Pembrolizumab monotherapyKRAS mutationsClinical utilityMutational burdenMutation statusPD-L1 tumor proportion scoreStandard first-line treatmentEGFR/ALK alterationsAdvanced PD-L1First-line treatmentPD-L1 expressionTumor proportion scorePlatinum-based chemotherapyDeath ligand 1Cell lung cancerPotential predictive biomarkersCut pointsKRAS mutation statusRetrospective exploratory analysis
2010
Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy
Haura EB, Camidge DR, Reckamp K, Chiappori A, Johnson F, Herbst R, Wong K, Carbone D. Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy. Journal Of Thoracic Oncology 2010, 5: s207-s213. PMID: 20502275, DOI: 10.1097/jto.0b013e3181e2f682.Peer-Reviewed Original ResearchConceptsLung cancerPersonalized preventionLung cancer preventionCancer risk reductionCancer stem cellsCancer preventionClinical utilityMouse modelCancer advocatesTumor microenvironmentCancerEarly detectionMeeting presentationsPreventionRisk reductionTherapyStem cellsClinical workTreatmentChemopreventionImportant relevanceGenome-wide approaches